表紙
市場調查報告書

藥品價格和醫療費用報銷:全球市場

Pharmaceutical Pricing and Reimbursement: Global Markets

出版商 BCC Research 商品編碼 948545
出版日期 內容資訊 英文 164 Pages
訂單完成後即時交付
價格
藥品價格和醫療費用報銷:全球市場 Pharmaceutical Pricing and Reimbursement: Global Markets
出版日期: 2020年07月09日內容資訊: 英文 164 Pages
簡介

預計到2024年,全球製藥市場將從2019年的1.580萬億美元增至1.52萬億美元,預計2019年至2024年的複合年增長率為7.5%。

本報告調查了過去10年中全球藥品市場的藥品價格和醫療費用報銷,全球藥品市場中醫療體系的改革和法規及其對行業併購和風險資本家投資的影響。美國和歐洲的分析,藥品定價和報銷政策和程序,以及有關如何投資仿製藥,生物仿製藥,非處方藥(OTC),小分子和生物製劑的評論。

第1章簡介

  • 研究目的
  • 調查原因
  • 報告範圍
  • 信息來源
  • 調查方法
  • 區域細分
  • 分析師職業
  • BCC海關調查
  • BCC研究相關報告

第2章摘要摘要

第3章全球醫療保健支出,法律和定價機制

  • 全球醫療費用
  • COVID之前的預測
  • COVID之後的預測
  • 對COVID-19緊急治療的反應
  • 擴展低成本數字服務
  • COVID-19的研發資金
  • 藥品支出
  • 北美
  • 歐洲
  • 日本
  • 金磚四國
  • COVID-19對2020年第一季度藥品銷售的影響
  • 併購(併購)
  • 2019年之前的併購活動
  • 2019併購活動
  • 2020年第一季度的併購活動
  • 醫療改革
  • 法國
  • 德國
  • 意大利
  • 西班牙
  • 英國
  • 美國
  • 藥品監管
  • 法國
  • 德國
  • 意大利
  • 西班牙
  • 英國
  • 美國
  • COVID-19對醫療保健的急性影響
  • 法國
  • 德國
  • 意大利
  • 西班牙
  • 英國
  • 美國

第4章定價策略

  • 簡介
  • 藥品成本上漲的主要原因
  • 用更新,更昂貴的藥物代替舊的低成本藥物
  • 增加使用藥物
  • 無法治癒的疾病新藥
  • 現有藥品的價格上漲
  • 藥品定價策略
  • 外部價格參考
  • 內部參考價
  • 處方藥價格
  • 英國
  • 美國
  • 非處方藥(OTC)價格
  • 歐洲
  • 英國
  • 美國
  • 仿製藥價格
  • 英國
  • 美國
  • 稀有藥品價格
  • 基於價值的定價
  • 公開招標和採購
  • 框架協議方法/框架協議

第5章醫療費用報銷策略

  • 藥品兌換
  • 批准醫療報銷
  • 醫療費用報銷程序
  • 歐洲
  • 英國
  • 美國
  • 報銷醫院醫療費用
  • 歐洲
  • 英國
  • 美國
  • 患者訪問方案
  • 財務基礎計劃
  • 基於結果的方案
  • 及早獲得毒品計劃
  • 歐洲
  • 英國
  • 美國
  • 處方清單
  • 歐洲
  • 英國
  • 美國
  • 醫療技術評估(HTA)
  • 歐洲
  • 英國
  • 美國
  • 成果研究的價值(HEOR)
  • HEOR十大趨勢

第6章未來

  • 擴大採用基於價值的定價方案
  • 增加對細胞/基因治療的投資
  • 創新的付款方式
  • 英國脫歐更加清晰
  • 關於藥品價格的政治爭議
  • 對COVID-19的長期反應尚不清楚

第7章參考

目錄
Product Code: PHM189A

Highlights:

The global pharmaceuticals market was valued at $1,058 billion in 2019 and should reach $1,520 billion by 2024 with a compound annual growth rate (CAGR) of 7.5% from 2019 to 2024.

Report Scope:

This new report on pricing and reimbursement in a global market provides a brief overview on the pharmaceutical markets, healthcare reforms and regulations across the globe over the last decade and how this has impacted mergers and acquisitions and venture capitalist investment in the sector. It reviews pricing and reimbursement policies and processes in the U.S. and Europe and the ways in which pharmaceutical investment in generics, biosimilars, over the counter (OTC), small molecule and biological agents; and the shift toward more innovative medicines such as cell and gene therapies may change future treatment paradigms and future pricing and reimbursement policies.

Report Includes:

  • An overview of the global markets for pharmaceuticals, specifically healthcare legislation and regulation, pricing mechanisms, and reimbursement procedures
  • Analyses of the global market trends, with data corresponding to market size for 2014-2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on the current price and reimbursement landscape, benchmarking statics, and future development opportunities in the pharma industry
  • Case studies of different price and reimbursement strategies for prescription drugs, orphan drugs, generics, over-the-counter products, and value-based pricing
  • Discussion on the impact of COVID-19 on pharmaceutical sales in Q1 2020 and overall healthcare marketplace
  • Insight into the greater adoption of value-based pricing schemes, with emphasis on the innovative payment models, increased investment in cell and gene therapies, and long-term response to COVID-19

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Global Healthcare Expenditures, Legislation and Pricing Mechanisms

  • Global Healthcare Costs
  • Forecasts Pre-COVID
  • Forecasts Post-COVID
  • Acute Healthcare Response to COVID-19
  • Expansion of Low-Cost Digital Services
  • Funding for COVID-19 Research and Development
  • Drug Expenditures
  • North America
  • Europe
  • Japan
  • BRIC Economies
  • Impact of COVID-19 on Pharmaceutical Sales in Q1 2020
  • Mergers and Acquisitions (M&A)
  • M&A Activity Pre-2019
  • M&A Activity in 2019
  • M&A Activity in Q1 2020
  • Healthcare Reforms
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
  • Pharmaceutical Regulation
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
  • Acute Impact of COVID-19 on Healthcare
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States

Chapter 4 Pricing Strategies

  • Introduction
  • Primary Reasons for the Rise in the Cost of Pharmaceuticals
  • Replacement of Older, Lower-Cost Drugs by Newer, Higher Priced Drugs
  • Increased Use of Drugs
  • New Drugs for Diseases for Which No Treatment Was Previously Available
  • Increases in the Prices of Existing Medicines
  • Pharmaceutical Pricing Strategies
  • External Price Referencing
  • Internal Referencing Pricing
  • Prescription Drug Pricing
  • United Kingdom
  • United States
  • Over-the-Counter (OTC) Drug Pricing
  • Europe
  • United Kingdom
  • United States
  • Generic Drug Pricing
  • United Kingdom
  • United States
  • Orphan Drug Pricing
  • Value-Based Pricing
  • Open Tender Invitations and Procurement
  • Framework Agreements

Chapter 5 Reimbursement Strategies

  • Pharmaceutical Reimbursement
  • Admission to Reimbursement
  • Reimbursement Procedure
  • Europe
  • United Kingdom
  • United States
  • Hospital Reimbursement
  • Europe
  • United Kingdom
  • United States
  • Patient Access Schemes
  • Financially Based Schemes
  • Outcome-Based Schemes
  • Early Access to Medicines Schemes
  • Europe
  • United Kingdom
  • United States
  • Formulary Lists
  • Europe
  • United Kingdom
  • United States
  • Health Technology Assessments (HTA)
  • Europe
  • United Kingdom
  • United States
  • The Value of Health Economics and Outcome Research (HEOR)
  • Top 10 HEOR Trends

Chapter 6 The Future

  • Greater Adoption of Value-Based Pricing Schemes
  • Increased Investment in Cell and Gene Therapies
  • Innovative Payment Models
  • Greater Clarity on Brexit
  • Political Wrangling Over Drug Prices
  • Long-term Response to COVID-19 Undefined

Chapter 7 References

List of Tables

  • Table 1 : Major Market Drivers of Global Healthcare Expenditures
  • Table 2 : Total Healthcare Expenditure in G20 Economies, 2018
  • Table 3 : Inpatient Care Average Length of Stay in All Hospitals, 2014
  • Table 4 : Steps Implemented to Access Diagnostics and Treatment Following the COVID-19 Pandemic
  • Table 5 : Steps Implemented to Boost and Optimize Healthcare Capacity
  • Table 6 : COVID-19 Vaccines under Development
  • Table 7 : COVID-19 Treatments under Development
  • Table 8 : Major Mergers and Acquisitions in the Global Pharmaceutical Market, 2019
  • Table 9 : Major M&A Deals in the Global Pharmaceutical Market, Q1 2020
  • Table 10 : Allowed Growth Rates, 2014-2018
  • Table 11 : Net Revenues Retained in the U.S. Pharmaceutical Market, by Type of Prescription Drug Participant, 2016
  • Table 12 : Pricing of Medicines in Europe
  • Table 13 : Using Market Forces to Price Generics in the U.K.
  • Table 14 : Pricing Policies for Biosimilars in Europe, as of April 2017
  • Table 15 : National Authorities in Charge of Market Authorization, Pricing and Reimbursement in the EU5 Countries
  • Table 16 : Federally Funded Health Insurance Programs in the U.S.
  • Table 17 : An Overview of Early Access Schemes
  • Table 18 : Example of a Five-Tier Formulary System in the U.S.
  • Table 19 : Acronyms Used in the Global Pharmaceutical Pricing and Reimbursement Market

List of Figures

  • Figure 1 : Projected Annual Growth in Global Healthcare Spending, 2020
  • Figure 2 : Global GDP Growth Forecast Comparison, February 2020 vs. May 2020
  • Figure 3 : Overview of Coronavirus Impact Index, by Industry
  • Figure 4 : Potential Initial Impact of Partial or Complete Shutdowns on Activity in the G7 Economies
  • Figure 5 : Schematic Diagram of Global Healthcare Spend to Increase, 2020
  • Figure 6 : Trends in Global Pharmaceuticals Sales, by Market Segment, 2018-2024
  • Figure 7 : Projected Annual Growth Forecast in Global Pharmaceutical Market, by Region Group, 2018-2022
  • Figure 8 : Market Shares of Generic Medicine Sales in Selected European Countries, as of 2016
  • Figure 9 : Cumulative Pharmaceutical M&A Spending Comparison, 2019 vs. 2018
  • Figure 10 : Healthcare Reforms in Germany
  • Figure 11 : Worldwide Confirmed Cases and Number of Fatalities from COVID-19, as Reported by WHO, as of May 24, 2020
  • Figure 12 : Regional Confirmed Cases and Number of Fatalities from COVID-19, as Reported by WHO, as of May 24, 2020
  • Figure 13 : European Countries Where External Reference Pricing is Used
  • Figure 14 : Overview of Countries that Refer to the U.K.
  • Figure 15 : European Countries Where Internal Reference Pricing is Used
  • Figure 16 : NHS Spending on Prescription Pharmaceuticals, 2010-2018
  • Figure 17 : Pharmaceutical Pricing Process in the U.S.
  • Figure 18 : Countries Using Generic Prices in Europe
  • Figure 19 : Share of Generic Drug Sales (by Value and Volume) Across the OECD Nations, 2014
  • Figure 20 : Comparing Prices of Biosimilars and Branded Products
  • Figure 21 : U.S., EU and Japan Orphan Designations per Year and Cumulative, 1983-2016
  • Figure 22 : Top 100 Orphan Drug Costs per Patient per Year in the U.S., 2012-2016
  • Figure 23 : Value-Based Pricing Process in the U.K.
  • Figure 24 : Overview of Pharmaceutical Tendering Process
  • Figure 25 : Overview of the Application of Reimbursement Schemes in Europe
  • Figure 26 : Organization of the U.S. Healthcare System
  • Figure 27 : U.S. Healthcare Expenditures as a Share of GDP, by Source of Funds, 1987-2018
  • Figure 28 : Organization of the Healthcare System in England
  • Figure 29 : Evolution of PAS England, 2007-2015
  • Figure 30 : PAS Approval Process (Simplified Version)
  • Figure 31 : Pathways for Accessing an Orphan Therapy in the EU
  • Figure 32 : Three-Stage EAMS Process in the U.K.
  • Figure 33 : Types of Reimbursement Lists Used in the Outpatient Sector Europe
  • Figure 34 : Process of Identifying if an Item Can be Prescribed on the NHS
  • Figure 35 : Two Simplified Examples of HTA Utilization in Europe
  • Figure 36 : Tools and Disciplines Involved HEOR Analysis
  • Figure 37 : Elements of Value-Based Pricing
  • Figure 38 : Global Cell and Gene Therapy Market, 2018 vs. 2024
  • Figure 39 : Innovative Payment Models for Cell and Gene Therapies
  • Figure 40 : Four Waves of COVID-19 on Healthcare